Independent register of U.S. FDA drug recalls · updated Oct 13, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,543 recalls, newest first.

Class II · Moderate risk

Lactulose Solution

Microbial Contamination of Non-Sterile Products: bulk solution tested positive for the presence of the bacteria, Burkholderia cepacia.

Terminated Microbial contamination VistaPharm, Inc. NDC 66689-039-01 D-0146-2017
Class II · Moderate risk

L-Cysteine Hydrochloride Injection

Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.

Terminated Sterility / contamination Sandoz Inc NDC 66758-005-01 D-0141-2017
Class II · Moderate risk

L-Cysteine Hydrochloride Injection

Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.

Terminated Sterility / contamination Sandoz Inc NDC 66758-004-01 D-0140-2017
Class II · Moderate risk

Papa/Phen/Prost

Lack of Assurance of Sterility: product produced on a day there was an excursion in environmental monitoring data.

Terminated Sterility / contamination Fallon Wellness Pharmacy, L.L.C. D-0174-2017
Class II · Moderate risk

Papa/Phen/Prost

Lack of Assurance of Sterility: product produced on a day there was an excursion in environmental monitoring data.

Terminated Sterility / contamination Fallon Wellness Pharmacy, L.L.C. D-0173-2017
Class II · Moderate risk

Metformin Hydrochloride Tablets

Presence of Foreign Tablets/Capsules; report of Amlodipine Tablets found in 1000 count bottles of Metformin Hydrochloride Tablets USP

Terminated Particulate / foreign matter Ascend Laboratories LLC NDC 67877-217-10 D-0163-2017
Class II · Moderate risk

Salsalate Tablets

CGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.

Terminated Wrong potency / content Nationwide Laboratories, LLC NDC 42937-704-10 D-0166-2017
Class II · Moderate risk

Salsalate Tablets

CGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.

Terminated Wrong potency / content Nationwide Laboratories, LLC NDC 42937-703-18 D-0165-2017

Recalls by year